Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wuxi Biologics (Cayman) (WXIBF) Gets a Buy from UBS

Tipranks - Tipranks - Sat Mar 28, 1:04AM CDT

In a report released on March 25, from UBS maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$49.30. The company’s shares closed last Wednesday at HK$33.14.

Claim 30% Off TipRanks Premium

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wuxi Biologics (Cayman) with a HK$45.23 average price target, which is a 36.49% upside from current levels. In a report released yesterday, CMB International Securities also maintained a Buy rating on the stock with a HK$39.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Wuxi Biologics (Cayman)’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of HK$9.95 billion and a net profit of HK$2.34 billion. In comparison, last year the company earned a revenue of HK$8.57 billion and had a net profit of HK$1.5 billion

Read More on WXIBF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).